5 companies advancing ATTR assets in the wake of Wainua’s fail
AstraZeneca and Ionis’ Wainua failed to show significant cardiovascular benefit in a Phase 3 trial in ATTR-CM, an outcome analysts said likely reduces odds of filing for that indication. The article reviews other ATTR-CM programs: AstraZeneca’s cliramitug (DepleTTR-CM, ~1,200 patients), Novo Nordisk’s coramitug (CLEOPATTRA, recruiting), Alnylam’s nucresiran (TRITON-CM, completion 2030), and Intellia’s nex-z (MAGNITUDE).
How this was made
The 30-second read
Why it matters
The piece is a field survey of ongoing ATTR-CM programs, highlighting how Wainua’s failure changes perceived probability of success and the perceived adequacy of endpoints across modalities.
Market read
Traders may use the article to re-rank ATTR-CM development risk by modality, but it does not introduce new trial results or decisions for most companies.
What to watch
The article emphasizes mechanistic rationale but underweights differences in baseline disease stage, endpoint sensitivity, and background stabilizer use, which can dominate trial outcomes more than the platform label.
Background
Wainua (approved for ATTR-PN) failed to show cardiovascular benefit in a Phase 3 ATTR-CM trial, prompting analysts to reassess what constitutes a successful ATTR-CM study.
Ticker impact
AstraZeneca’s ATTR-CM Phase 3 DepleTTR-CM program continues with cliramitug after Wainua’s ATTR-CM failure reshaped expectations.
Near-term sentiment likely volatile, with upside skew if DepleTTR-CM enrollment and interim signals hold; otherwise risk premium may rise.
The article is a field read-through, not a new AZN-specific datapoint, but it highlights AZN’s ongoing Phase 3 and the rationale from prior first-in-human durability results.
Ionis is named as co-developer of Wainua, whose ATTR-CM Phase 3 failure likely reduces odds of filing for that indication.
Potential downside bias versus peers until Ionis clarifies next steps or shows ATTR-CM success elsewhere.
The article explicitly ties Wainua’s failure to reduced likelihood of AstraZeneca and Ionis filing for ATTR-CM, which is a concrete strategic implication for Ionis.
Novo Nordisk advances coramitug into Phase 3 CLEOPATTRA in ATTR-CM after Wainua’s failure heightened the bar for successful trials.
Moderate upside optionality if CLEOPATTRA confirms biomarker-to-clinical translation; otherwise higher risk premium for ATTR-CM programs.
This is not a new coramitug result, but the article provides specific Phase 2 biomarker context and regulatory Fast Track, which traders can use to reassess risk.
Alnylam’s nucresiran is flagged as facing “raises questions” after Wainua’s ATTR-CM failure, challenging silencer efficacy amid background stabilizers.
Near-term sentiment likely pressured for ATTR-CM-focused RNAi assets; relative support may come from ATTR-PN trial timelines and Amvuttra revenue.
The article includes an explicit analyst critique and ties it to nucresiran’s ATTR-CM development, but it does not disclose new ALNY trial data.
Intellia’s nex-z gene therapy is discussed as an alternative ATTR approach, with Phase 3 MAGNITUDE/MAGNITUDE-2 data timing potentially affected by the post-Wainua landscape.
Limited immediate impact without new nex-z data, but watchlist-level upside if investors rotate toward modalities with differentiated mechanisms.
The article provides trial descriptions and data timing but no new nex-z results or regulatory actions.
Market effects
ATTR-CM trial success criteria are questioned, likely increasing discount rates for similar mechanisms and boosting relative interest in amyloid-depleting or alternative modalities.
Primarily US-listed biotech sentiment spillover, with global pharma (AZN) and European biotech investors reacting to the same clinical read-through.
Could shift global ATTR-CM development strategies and endpoint expectations across the rare-disease cardiomyopathy pipeline.
Counterpoint
Wainua’s failure may not generalize across mechanisms; coramitug and cliramitug have different biology and may still succeed if endpoints and background therapy are properly matched.
Key entities
- companyAstraZeneca
Advancing cliramitug in Phase 3 DepleTTR-CM after Wainua’s ATTR-CM failure reshaped expectations.
- companyIonis Pharmaceuticals
Co-developer of Wainua; the article says filing for ATTR-CM is unlikely after the Phase 3 flop.
- companyNovo Nordisk
Advancing coramitug into Phase 3 CLEOPATTRA in ATTR-CM; Fast Track granted.
- companyAlnylam
Nucresiran ATTR-CM prospects questioned by analysts after Wainua’s failure; ATTR-PN and Amvuttra context provided.
- companyIntellia Therapeutics
Gene therapy nex-z in Phase 3 MAGNITUDE/MAGNITUDE-2 with potential data timing in 2027.
